Ontology highlight
ABSTRACT: Background and purpose
Esophageal cancer has a persistently low 5-year survival rate and has recently been classified as a cancer of unmet need by Cancer Research UK. Consequently, new approaches to therapy are urgently required. Here, we tested the hypothesis that an ATR inhibitor, VX-970, used in combination with standard therapies for esophageal cancer could improve treatment outcome.Material and methods
Using esophageal cancer cell lines we evaluated the efficacy of combining VX-970 with cisplatin and carboplatin in vitro and with radiation in vitro and in vivo. Radiation experiments were also carried out in hypoxic conditions to mimic the tumor microenvironment.Results
Combining VX-970 with cisplatin, carboplatin and radiation increased tumor cell kill in vitro
SUBMITTER: Leszczynska KB
PROVIDER: S-EPMC5154234 | biostudies-literature | 2016 Nov
REPOSITORIES: biostudies-literature